Gastroenterology Learning Network

Siddarth Singh: AGA Guidelines on Using Biomarkers in Ulcerative Colitis by Gastroenterology Learning Network

Dr Millie Long and her IBD Drive Time cohost, Dr Raymond Cross, talk about ways health insurers create barriers to timely treatment for inflammatory bowel disease, particularly through requirements for prior authorization.

Drs Ryan Ungaro and Priscila Santiago on Risk Factors Predicting Complicated IBD by Gastroenterology Learning Network

Dr Brian Lacy welcomes Dr Timothy Gardner to talk about acute pancreatitis.

Eric Benchimol, MD, on Pediatric IBD: The Year in Review by Gastroenterology Learning Network

The results of the ATLANTIS trial showed that patients taking amitriptyline were almost twice as likely to report an overall improvement in symptoms of irritable bowel syndrome as those taking a placebo. Co-chief investigator Alexander Ford, MD, explains the results and the implications.

In this podcast, Dr Lea Ann Chen explains how race/ ethnicity (White, Black, Hispanic, Asian) and immigration status (US-born vs foreign-born) influence IBD manifestations, disease onset, treatments, and outcomes.

Rita Knotts, MD, and Justin Henning, MD, on Diagnosing and Treating Hiatal Hernia by Gastroenterology Learning Network

In this episode of IBD Drive Time, guest Dr Adjoa Anyane-Yeboa of Massachusetts General Hospital talks with guest host Dr David Rubin of the University of Chicago about how social determinants of health can affect diagnosis and treatment of inflammatory bowel disease among marginalized communities.

Gut Check: Brian Lacy, MD, and Megan Riehl, PsyD by Gastroenterology Learning Network

Dr Cohen discusses with host Dr Raymond Cross the recent guidelines published by the American Gastroenterological Association on using biomarkers to monitor inflammatory bowel disease.

In this special podcast Dr Rita Knotts, with the Center for Esophageal Health at NYU-Langone, and Dr Elizabeth Volkmann, founder and codirector of the UCLA Connective Tissue Disease-Related Interstitial Lung Disease, discuss the intersection of their specialities in the care of patients with scleroderma, interstitial lung disease, and esophageal conditions such as reflux.

In this episode of IBD DriveTime, Dr Manasi Agrawal of Mt Sinai Hospital in New York discusses her research into surgery as a first-line therapy for Crohn's disease with host Dr Raymond Cross.

IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD by Gastroenterology Learning Network

Dr Brian Lacy interviews Dr Douglas Drossman on the definition, causes and treatment for disorders of gut-brain interaction.

Dr Raymond Cross quizzes Dr Frank Farraye on the latest guidance regarding vaccinations against COVID-19 and RSV in this episode of IBD DriveTime.

In this episode of Gut Check, guest Linda Nguyen, MD, from Stanford University, and host Brian Lacy, MD, from Mayo Clinic Florida, talk about recent updates to the American College of Gastroenterology guideline on diagnosing and managing gastroparesis.

Guest Michael Dolinger, MD, from the Icahn School of Medicine at Mount Sinai, talk to host Millie Long, MD, about the use and advantages of intestinal ultrasound for monitoring inflammatory bowel disease.

In this episode of IBD Drive Time, guest host David Rubin, MD, calls on Drs Severine Vermeire of KU Leuven University in Belgium and Dan Tucker of Hebrew University of Jerusalem to talk about the challenges of recruiting patients for clinical trials in inflammatory bowel disease and the ethical issues involved.

Dr Scott discusses the development of a pathway based on specific diagnostic criteria that indicate the need to refer patients with inflammatory bowel disease to specialist centers.

In the latest IBD Drive Time, host Raymond Cross, MD, talks with Ryan Stidham, MD, about potential applications for artificial intelligence and ChatGPT in gastroenterology practice—and what is feasible right now.

Drs Brian Lacy and Mark Pimentel provide an update on the progress in diagnosing and treating small intestinal bacterial overgrowth and a similar condition, intestinal methanogen overgrowth (IMO).

Dr Edward Loftus reviews details of the pivotal trial where upadacitinib emerged a superior alternative to placebo for induction and maintenance therapy among patients with moderate-to-severe Crohn’s disease.

In this podcast, Dr Adam Faye explains the association between various patient-level demographic, nutritional and clinical factors and risk for complications among older patients who underwent intestinal resection for inflammatory bowel disease. -- Adam Faye, MD, is an assistant professor of medicine and population health at the Inflammatory Bowel Disease Center at NYU Langone Health. --

Dr Gil Melmed from Cedars-Sinai talks with Drs Raymond Cross and Millie Long about the importance of vaccines, cancer screenings, and other aspects of overall health maintenance for patients with inflammatory bowel disease.